Treatment Options for Idiopathic Interstitial Pneumonias

Nonspecific Interstitial Pneumonia (NSIP) Treatment

The American Thoracic Society recommends corticosteroids as the first-line treatment for NSIP, with most patients showing improvement after treatment 1
Initial therapy typically consists of prednisone at immunosuppressive doses, which should be started at the first identification of clinical or physiological impairment 2
The majority of NSIP patients have a good prognosis with an estimated 15-20% mortality at 5 years 1

The American Thoracic Society concludes that no data exist that adequately document any current treatment approaches improve survival or quality of life for patients with IPF/UIP 2
Corticosteroid therapy (with or without immunomodulator therapy) is not recommended in patients with a definite diagnosis of IPF/UIP 3
N-acetylcysteine (NAC) may be considered for some patients with UIP/IPF after evaluating the benefit/risk ratio and patient preferences 3

Surgical lung biopsy (preferably via video-assisted thoracoscopy) is recommended to distinguish UIP from other forms of idiopathic interstitial pneumonia, including NSIP 4, 5
NSIP shows homogeneous appearance of either inflammation or fibrosis with temporally uniform changes 1
UIP is characterized by marked fibrosis with architectural distortion, patchy involvement, and fibroblastic foci 3
HRCT in NSIP typically shows bilateral symmetric ground glass opacities or bilateral air space consolidation 1

Treatment should be started at the first identification of clinical or physiological impairment or documentation of decline in lung function 2
A combination of clinical, radiographical, and physiological parameters should be used to assess the clinical course and response to treatment 2
Lung transplantation should be considered for patients who experience progressive deterioration despite treatment 2
The potential risks of surgical lung biopsy need to be balanced against the accuracy of clinical diagnosis and likelihood of identifying a more treatable form of interstitial lung disease 4

The American Thoracic Society (ATS) acknowledges antifibrotic agents as treatment options for progressive fibrotic disease, though definitive mortality benefit remains unproven 6
UIP/IPF carries significantly worse prognosis than NSIP, with mean survival of 2-4 years and 5-year survival ranging 30-50% 7
Patients with definite UIP pattern on HRCT have shorter survival than those with indeterminate findings 8, 9
NSIP has significantly better prognosis than UIP/IPF, with estimated 15-20% mortality at 5 years, and some patients improve or remain stable on treatment, while others evolve to end-stage fibrosis 8, 9

NSIP is characterized by bilateral ground-glass opacity, with subpleural sparing, and sparse or absent honeycombing at presentation 8, 9
UIP is characterized by subpleural and basal predominant distribution with honeycombing and/or traction bronchiectasis, and a heterogeneous pattern with areas of normal lung interspersed with fibrosis 10
NSIP shows varying amounts of interstitial inflammation and fibrosis with temporally uniform appearance, and honeycomb fibrosis should be inconspicuous or absent 8, 9

Pirfenidone can be considered for progressive pulmonary fibrosis with UIP pattern, though evidence remains limited 6
The ATS/ERS/JRS/ALAT guidelines recommend antifibrotic agents as treatment options for progressive fibrotic disease 6